Table 1.
Clinical and demographic characteristics of research subjects.
| Subjects Not on Biologics (NB) from Immunologically Healthy Control (IHC) cohort | Patients on Biologics (PoB) | |
|---|---|---|
| Number of subjects | 46 | 57 |
| Average months on biologic prior to enrolment | n/a | 22 |
| Demographics | ||
| Average Age | 38 | 54 |
| Male | 14 (30%) | 24 (42%) |
| Female | 32 (70%) | 33 (58%) |
| White | 27 (60%) | 26 (46%) |
| Black | 7 (16%) | 20 (35%) |
| Asian | 10 (22%) | 7 (12%) |
| Other | 1 (2%) | 4 (7%) |
| Average body mass index | 26 | 31 |
| Current smokers | 0 (0%) | 2 (4%) |
| Former smokers | 6 (13%) | 9 (16%) |
| Never smokers | 39 (87%) | 46 (81%) |
| Type of vaccine received | ||
| Pfizer-BioNTech | 30 (67%) | 36 (63%) |
| Moderna | 15 (33%) | 21 (37%) |
| Underlying clinical condition | ||
| Subjects with asthma | 9 (20%) | 47 (82%) |
| Subjects without asthma | 37 (80%) | 10 (18%) |
| Subjects with atopic dermatitis | 0 (0%) | 19 (33%) |
| Subjects with both asthma and atopic dermatitis | 0 (0%) | 9 (16%) |
| Clinical characteristics of subjects with asthma | ||
| Asthma exacerbations in the previous year | 6 | 22 |
| Asthma exacerbations per subject with asthma in the previous year | 0.67 | 0.47 |
| Subjects with asthma on low dose ICS | 1 of 9 (11%) | 2 of 47 (4%) |
| Subjects with asthma on medium dose ICS | 2 of 9(22%) | 17 of 47 (36%) |
| Subjects with asthma on high dose ICS | 3 of 9 (33%) | 16 of 47(34%) |
| Subjects with asthma not on ICS | 3 of 9 (33%) | 12 of 47 (26%) |
| Subjects on ≥5 mg oral prednisone daily | 1 of 9 (11%) | 3 of 47 (9%) |